US Stock MarketDetailed Quotes
SCNI Scinai Immunotherapeutics
- 3.460
- -0.020-0.57%
Close Nov 27 16:00 ET
- 3.460
- 0.0000.00%
Post 20:01 ET
2.95MMarket Cap1.44P/E (TTM)
3.751High3.411Low40.18KVolume3.475Open3.480Pre Close141.82KTurnover5.39%Turnover RatioLossP/E (Static)853.00KShares8.92052wk High0.67P/B2.58MFloat Cap2.23052wk Low--Dividend TTM745.16KShs Float6199.990Historical High--Div YieldTTM9.77%Amplitude2.230Historical Low3.529Avg Price1Lot Size
Scinai Immunotherapeutics Stock Forum
Sign in to post a comment
NOTE: NFA. Do not open position without buy pressure, volume. Check indicators, chart.
I see more Quantum play this week.
$Quantum (QMCO.US)$ AWS launched QuantumEmbark. Up after hours. Small float. 0 shares LTB.
$Arqit Quantum (ARQQ.US)$ AWS launched Quantum Embark.Increased market cap which translates to stock increasing in stock value and increased confidence in the stock. Low floa...
I see more Quantum play this week.
$Quantum (QMCO.US)$ AWS launched QuantumEmbark. Up after hours. Small float. 0 shares LTB.
$Arqit Quantum (ARQQ.US)$ AWS launched Quantum Embark.Increased market cap which translates to stock increasing in stock value and increased confidence in the stock. Low floa...
57
8
$Scinai Immunotherapeutics (SCNI.US)$ would this still go up despite its good ER even with its questionable outlook under trump?
$Scinai Immunotherapeutics (SCNI.US)$ Press Release: Scinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up From Negative $7.3 Million as of June 30, 2024, to Positive $10 Million
Dow Jones· 4 mins ago
Dow Jones· 4 mins ago
2
1
$Scinai Immunotherapeutics (SCNI.US)$
Scinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million
Scinai Immunotherapeutics (NASDAQ: SCNI) reported financial results for the nine months ended September 30, 2024.
The company's shareholders' equity improved to positive $10 million from negative $7.3 million, primarily due to the conversion of a EUR 26.6 million EIB loan into preferred shares.
R...
Scinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million
Scinai Immunotherapeutics (NASDAQ: SCNI) reported financial results for the nine months ended September 30, 2024.
The company's shareholders' equity improved to positive $10 million from negative $7.3 million, primarily due to the conversion of a EUR 26.6 million EIB loan into preferred shares.
R...
$Scinai Immunotherapeutics (SCNI.US)$ Scinai Regains Full Compliance with Nasdaq Listing Requirements
9 MINUTES AGO, 6:31 AM EDT
VIA PR NEWSWIRE
9 MINUTES AGO, 6:31 AM EDT
VIA PR NEWSWIRE
1
Promising In-Vivo Results for Scinai Immunotherapeutics' Psoriatic Human Skin Model.
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biotechnology company known for its focus on developing inflammation and immunology (I&I) biological products, has announced successful in-vivo preclinical study results. The results pertain to its innovative anti IL-17A/F VHH antibody fragment, known as 'NanoAb', which fun...
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biotechnology company known for its focus on developing inflammation and immunology (I&I) biological products, has announced successful in-vivo preclinical study results. The results pertain to its innovative anti IL-17A/F VHH antibody fragment, known as 'NanoAb', which fun...
1
$Scinai Immunotherapeutics (SCNI.US)$ ah shit bag holding
1
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
MooMamaLlama : been riding novonix for cpl yrs, their synthetic graphite was going to attract attention, but adding an anode division to their cathode materials and battery tech was a smart move
70965684 : How much is the price? Thank you.
Jaguar8 OP 70965684 : Of what???
70965684 : Arqq
Jaguar8 OP 70965684 : Nah ARQQ is down 13.70
View more comments...